Deborah Diercks, MD
Associate Professor of Emergency Medicine
University of California Davis Medical Center
Department of Emergency Medicine
Donna L. Mason, RN, MS, CEN
Bluejay Consulting LLC
1.0 Contact Hour (0.1 CEU)
ACS continues to be a major source of morbidity and mortality in this country. Advances in medical therapy and new clinical data are constantly leading to updated guidelines and recommendations designed to improve patient outcomes. Emergency nurses work on the front lines of health care and are called upon to triage and manage these patients, so they must be well educated and follow guidelines appropriately. Bleeding risks should be minimized whenever possible, but not to the extent of undertreating patients. Hence, continuing education is needed to prepare and equip emergency nurses with the knowledge and confidence to utilize the most appropriate therapies when treating patients with STEMI and NSTEMI.
NOTE: This program was originally presented as an educational breakfast session at the 2008 Emergency Nurses Association Annual Conference in Minneapolis on September 26, 2008. If you received continuing nursing education contact hours for attending the session during the ENA Annual Conference, you are not eligible to receive contact hours by participating in this online activity.
. Target Audience
This educational activity is designed to meet the needs of emergency nurses and advanced practice nurses.
Upon completion of this educational activity, the participant should be able to:
Describe how the 2007 ACC/AHA guidelines for the management of STEMI and NSTEMI differ from previous guidelines
Utilize the 2007 ACC/AHA guidelines to apply appropriate treatment to ACS patients in the emergency department
Review best treatment options, including best options for community hospitals with limited facilities
Discuss specific patient characteristics that may affect treatment decisions
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.
Dr. Diercks discloses that she has served on speakers' bureaus for sanofi-aventis and Bristol-Myers Squibb Company. She has also served as a consultant for Astellas Pharma Inc., Bristol-Myers Squibb Company, Heartscape Technologies, Inc., The Medicines Company, and sanofi-aventis and has conducted contracted research for Dade-Behry.
Ms. Mason has no relevant financial interests to disclose.
This educational activity may contain discussion of published and/or investigational uses of pharmaceutical agents. Some uses of these agents may not have been approved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Credit Statements
Nurse Continuing Education: AKH Inc. is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. AKH Inc. designates this educational activity for 1.0 contact hours (0.1 CEUs).
There are no fees to participate and receive credit. Credit is awarded to participants who listen to the presentation in its entirety and complete an evaluation.
Commercial Support Statements
This activity is supported by an independent educational grant by sanofi-aventis U.S. and the Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership. Certificate Fee
©2008 Medical Communications Media, Inc. None of the contents may be reproduced in any form without prior written permission from the publisher. The opinions expressed in this educational program are those of the presenters and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, AKH Inc., or sanofi-aventis U.S. and the Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership. Any medications, diagnostic procedures, or treatments discussed by the program presenters should not be used by clinicians or other healthcare professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.